drugset / Trial / NCT01299558
Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects
Non-randomizedCrossoverOpen-labelOther
Summary
This study is being done to look at the absolute bioavailability of fluticasone furoate and GW642444 inhalation powder when administered in healthy subjects. Bioavailability is determined by measuring the amount of the dose of inhaled medication that reaches the circulation; the amount of inhaled fluticasone furoate and GW642444 powder will be compared to the medication administered intravenously (where bioavailability is 100%).
Timeline
- Start
- 2010-05-17
- Primary completion
- 2010-07-15
- Completion
- 2010-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluticasone Furoate | Other / unclassified | 250 ug | Inhaled |
| Subject | Fluticasone Furoate | Other / unclassified | 800 ug | Inhaled |
| Subject | Vilanterol | Other / unclassified | 55 ug | Inhaled |
| Subject | Vilanterol | Other / unclassified | 100 ug | Inhaled |